Argos Therapeutics Inc (NASDAQ:ARGS) insider Charles A. Nicolette sold 100,250 shares of the firm’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $0.16, for a total value of $16,040.00. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Shares of Argos Therapeutics Inc (ARGS) traded down $0.00 during trading hours on Friday, hitting $0.16. The company had a trading volume of 2,660,000 shares, compared to its average volume of 3,330,477. The company has a current ratio of 2.29, a quick ratio of 2.29 and a debt-to-equity ratio of -1.46. Argos Therapeutics Inc has a 1-year low of $0.13 and a 1-year high of $5.50.
An institutional investor recently bought a new position in Argos Therapeutics stock. Wasatch Advisors Inc. bought a new position in Argos Therapeutics Inc (NASDAQ:ARGS) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 665,831 shares of the biopharmaceutical company’s stock, valued at approximately $120,000. Wasatch Advisors Inc. owned approximately 1.21% of Argos Therapeutics at the end of the most recent quarter. Institutional investors own 18.35% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Charles A. Nicolette Sells 100,250 Shares of Argos Therapeutics Inc (ARGS) Stock” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/14/charles-a-nicolette-sells-100250-shares-of-argos-therapeutics-inc-args-stock.html.
Argos Therapeutics Company Profile
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.